Abstracts tagged "Autoantibodies and myositis"

Abstract Number: 1346 • 2018 ACR/ARHP Annual Meeting
Anti-NT5c1A Autoantibodies As Biomarkers in Inclusion Body Myositis
Adam Amlani¹, Mark Tarnopolsky², Lauren Brady², Ignacio Garcia de la Torre³, Michael Mahler⁴, May Choi⁵ and Marvin J. Fritzler⁵, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Pediatrics and Medicine, McMaster University Medical Center, Hamilton, ON, Canada, ³University of Guadalajara, Guadalajara, Mexico, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Sporadic Inclusion Body Myositis (sIBM) is an insidious onset, idiopathic inflammatory myopathy (IIM) with high morbidity. There has not been a reliable biomarker to…
Abstract Number: 1267 • 2014 ACR/ARHP Annual Meeting
Are Anti-SRP Auto-Antibodies Specific for Myositis?
Samantha Rodriguez-Muguruza¹, Ines Lozano², Jaume Coll³, Maria Lourdes Mateo¹, Susana Holgado¹, Eva Martínez-Cácerez² and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³Neurology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Background/Purpose . Myositis-specific auto-antibodies (Ab) include those directed against aminoacyl-tRNA synthetases (ARS), signal recognition particle (SRP) and nuclear helicase Mi-2. Anti-SRP Ab are among the…
Abstract Number: 2064 • 2013 ACR/ARHP Annual Meeting
An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies To Nuclear Pore Complexes ‒ Description and Long-Term Follow-Up Of The Anti-Nup Syndrome
Catherine Isabelle¹, Marie-Christine Dabauvalle², Marvin J. Fritzler³, Ira N. Targoff⁴, Rose Goldstein⁵, Yves Troyanov¹, Michel Gagné¹, Jean-Pierre Raynauld¹ and Jean-Luc Senécal¹, ¹Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²University of Würzburg, Würzburg, Germany, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis encompasses various myositis-overlap syndromes, each one being identified by the presence of serum marker autoantibodies. We describe a novel myositis-overlap syndrome in…
Abstract Number: 2068 • 2013 ACR/ARHP Annual Meeting
Comparison Of Radioimmunoprecipitation Versus Antigen Specific Assays For Identification Of Myositis Specific Autoantibodies In Dermatomyositis Patients
Eun Ha Kang¹, Eun Young Lee², Yun Jong Lee³, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁴Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: To confirm the antigen specificities of autoantibodies that precipitate 140 kDa (anti-p140) or 155/140 kDa polypeptides (anti-p155/140) on radioimmunoprecipitation (RIP) in Korean patients with…
Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Rohit Aggarwal¹, Chester V. Oddis², Erich R Wilkerson³, Diane Koontz⁴, Ilinca D. Metes⁵, Ann M. Reed⁶, Dana P. Ascherman⁷ and Marc C. Levesque⁸, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…
Abstract Number: 1949 • 2012 ACR/ARHP Annual Meeting
Anti-Transcription Intermediary Factor 1-Gamma (TIF1-Υ) Autoantibody ELISA Development and Validation
Rohit Aggarwal¹, Chester V. Oddis², Noreen Fertig³, Danielle Goudeau⁴, Diane Koontz⁵, Chad Stephans⁶, Zengbiao Qi⁷ and Marc C. Levesque⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-transcription intermediary factor 1-gamma (TIF1-g) autoantibody is disease-specific for myositis and identifies a subset of dermatomyositis patients at risk of cancer. Currently non-quantitative immunoprecipitation…
Abstract Number: 1950 • 2012 ACR/ARHP Annual Meeting
Anti-Signal Recognition Particle Autoantibody ELISA Development and Validation: Utility in Patients with Necrotizing Myopathy
Rohit Aggarwal¹, Chester V. Oddis², Danielle Goudeau³, Chad Stephans⁴, Noreen Fertig⁵, Qi Zengbiao⁶, Diane Koontz⁶ and Marc C. Levesque³, ¹Rheumtology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-signal recognition particle (SRP) autoAb identifies a myositis subset with a necrotizing myopathy and poor prognosis. Currently, immunoprecipitation (IP) is used to identify anti-SRP.…
Abstract Number: 756 • 2012 ACR/ARHP Annual Meeting
Effect of B Cell Depletion Therapy with Rituximab On Myositis Associated Autoantibody Levels in Idiopathic Inflammatory Myopathy
Rohit Aggarwal¹, Chester V. Oddis², Andriy Bandos³, Danielle Goudeau⁴, Diane Koontz³, Qi Zengbiao³, Ann M. Reed⁵, Dana P. Ascherman⁶ and Marc C. Levesque⁷, ¹Rheumtology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immun, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis associated autoantibodies (MAA) in idiopathic inflammatory myopathy (IIM) demonstrate unique phenotypic features. In some autoimmune disorders, autoantibody levels correlate with disease activity and…
Abstract Number: 212 • 2012 ACR/ARHP Annual Meeting
Distinctive Characteristics of Anti-Mi-2 and –p155/140 Autoantibody Production in Two Cohorts of Mexican Patients with Dermatomyositis
Monica Vazquez-Del Mercado¹, Marcelo Petri¹, Luis J. Jara-Quezada², Miguel A. Saavedra-Salinas³, Claudia Cruz-Reyes⁴, Olga-Lidia Vera-Lastra⁵, Lilia Andrade⁶, Mario Salazar-Paramo⁷, Laura Gonzalez-Lopez⁸, Jorge Gamez-Nava⁹, Rosa E. Prieto-Parra⁷, Teresita Martin Marquez¹, Jason Y.F. Chan¹⁰, Edward K.L. Chan¹¹ and Minoru Satoh¹⁰, ¹Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ²Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ³Rheumatology, Centro Médico Nacional, México, Mexico, ⁴Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico, ⁵Rheumatology, Inst Mexicano Seguro Social, Mexico City, Mexico, ⁶CMN 20 Noviembre ISS STE, Mexico, Mexico, ⁷Clinical Research Division, Instituto Mexicano Del SS, Guadalajara, Mexico, ⁸Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, ⁹Rheumatology, Centro Medico de Occidente, Guadalajara Jal, Mexico, ¹⁰Medicine, University of Florida, Gainesville, FL, ¹¹Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Various autoantibodies associated with a unique subset of polymyositis/dermatomyositis (PM/DM), including antibodies to Jo-1 and other synthetases, SRP, Mi-2, PM-Scl and others, have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].